Preliminary efficacy results from an ongoing phase I/II trial of CTS2190, a PRMT1 inhibitor, in patients with advanced/metastatic solid tumors.

Authors: Jianan Jin, Jun Yao, Mingxi Wang, Huan Zhou, Qiming Wang, Tao Sun, Jie Lin, Lin Wu, Jing Yang, Jin Miao, Yuan Mi, Haiping Wu, Shuning Xing, Zhengbo Song

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.3082

Source: Full article


Abstract

3082